<DOC>
	<DOCNO>NCT02603458</DOCNO>
	<brief_summary>This study seek examine effectiveness NRX-1074 treatment negative symptom cognition schizophrenia compare agent glycine site demonstrate inconsistent result negative symptom . In addition test efficacy , examine time course response symptom well effect memory consolidation .</brief_summary>
	<brief_title>NRX-1074 Early Course Schizophrenia</brief_title>
	<detailed_description>Investigators propose conduct 4-week , randomize , double-blind , placebo-controlled trial NRX-1074 intravenously administer twice . Subjects 62 stable patient age 18-50 within five year onset schizophrenia , treat antipsychotic except clozapine adequate , stable dose least 8 week . This study conduct Schizophrenia Program NYU Langone Medical Center Psychiatry Outpatient Clinic Bellevue Hospital locate New York , NY . Upon sign consent , patient undergo screen procedure assess eligibility . A diagnosis schizophrenia schizophreniform disorder determine Structured Clinical Interview DSM IV ( SCID ) complete research clinician use available clinical data confirm consensus diagnosis . A comprehensive medical review physical exam , include routine laboratory test , complete identify unstable medical illness . A urine toxicology screen , female , pregnancy test also perform . A research assistant complete Logical Memory Test portion Weschler Memory Scale-III ( WMS-III ) . Subjects meet study eligibility criterion complete baseline visit include one minute infusion NRX-1074 follow clinical assessment : Brief Psychiatric Rating Scale ( BPRS ) , Clinical Assessment Interview Negative Symptoms ( CAINS ) , Calgary Depression Scale Schizophrenia ( CDSS ) , InterSePT Scale Suicidal Thinking ( ISST ) , Clinical Global Impression ( CGI ) , Systematic Assessment Treatment Emergent Events ( SAFTEE ) . The BPRS , SAFTEE , ISST conduct twice , infusion . The remain assessment conduct infusion . A cognitive assessment , Logical Memory Test WMS-III , also conduct infusion . Patients return visit one day baseline infusion , BPRS , ISST , CGI , Logical Memory Test conduct . Their next visit one week later , receive second NRX-1074 infusion , similar format first baseline infusion exception CAINS CDSS . One day second infusion , patient administer BPRS , CAINS , CDSS , ISST , CGI , MATRICS Consensus Cognitive Battery ( MCCB ) . Patients return weekly three week Day 28 . The BPRS ISST conduct Baseline , Day 1 , Day 7 , Day 8 , Day 14 , Day 21 , Day 28 visit . The CGI administer Baseline , Day 1 , Day 7 , Day 8 , Day 14 , Day 28 . The CAINS CDSS administer Baseline , Day 8 , Day 14 , Day 28 . The SAFTEE conduct Baseline , Day 7 , Day 14 , Day 21 , Day 28 . The Logical Memory Test administer Screening Visit 1 , Screening Visit 2 , Baseline , Day 1 . The MATRICS conduct Day 8 Day 28 . The primary outcome measure change BPRS total score Baseline 24 hour post infusion Day 8 . Secondary outcome measure include positive negative symptom subscales BPRS , CAINS total score , composite score MATRICS 24 hour second infusion Logical Memory Test compare placebo one hour first infusion ( Baseline ) .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<criteria>Age 1850 Diagnosis Schizophrenia , Schizophreniform , schizoaffective disorder per DSMV criterion Within five year onset illness Treated antipsychotic agent except clozapine adequate , stable dose least 8 week . A score least 4 ( moderate ) least one BPRS negative symptom item . Serious unstable medical illness Pregnant nursing Abuse substances except nicotine previous 6 week ( exclude cannabis use ) Positive urine toxicology screen Experiencing serious suicidal homicidal ideation within six month Treatment clozapine</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>50 Years</maximum_age>
	<verification_date>February 2016</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Naurex</keyword>
	<keyword>Intravenous Treatment</keyword>
	<keyword>NRX-1074</keyword>
</DOC>